抗布鲁氏菌药物安全性和有效性对比分析——利福平联合多西环素vs利福平联合复方新诺明
Journal: Basic Medical Theory Research DOI: 10.32629/bmtr.v8i3.20492
Abstract
目的：对比分析利福平联合多西环素（方案1）与利福平联合复方新诺明（方案2）在布鲁氏菌病治疗中的临床疗效及安全性。方法：收集我院2024年1月至2025年12月收治的308例布鲁氏菌病住院患者临床资料，其中方案1组180例，方案2组128例，比较两组患者的胃肠道不良反应率、症状改善时间、肝功能异常发生率、住院天数及住院费用等指标。结果：方案2组在胃肠道不良反应率（45% vs 63%）、肝功能异常发生率（26.7% vs 43.5%）、住院天数（5.9天 vs 8.2天）和住院费用（5.26千元 vs 6.37千元）方面均优于方案1组，但症状改善时间（3.8天 vs 2.5天）略长于方案1组。结论：利福平联合复方新诺明方案在整体安全性及卫生经济学指标方面具有优势，对特殊人群更为适用，可作为布鲁氏菌病基础治疗的重要选择。
Keywords
布鲁氏菌病；利福平；多西环素；复方新诺明；药物安全性
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] 潍坊市益都中心医院.布鲁菌病合并脊柱炎120例临床研究[J].中华实验和临床感染病杂志(电子版),2018,12(5).
[2] Alavi SM, Alavi L. Treatment of brucellosis: a systematic review of studies in recent twenty years[J]. Caspian Journal of Internal Medicine, 2013, 4(2): 636-641.
[3] Galvão EL, et al. Treatment of Childhood Brucellosis: A Systematic Review[J]. Pediatric Infectious Disease Journal, 2024, 43(9): 857-866.
[4] 中国创伤救治联盟新疆分中心.布鲁氏菌性骨关节炎诊断和治疗专家共识[J].中国组织工程研究,2026,30(9):2403-2412.
[5] 方千,等.神经型布鲁菌病的临床特点及诊治分析[J].中华实验和临床感染病杂志,2016,10(1).
[6] Hasanjani Roushan MR, et al. Comparison of the efficacy of two months of treatment with co-trimoxazole plus doxycycline vs. co-trimoxazole plus rifampin in brucellosis[J]. Swiss Medical Weekly, 2004, 134(37-38): 564-568.
[7] Huang S, et al. Updated therapeutic options for human brucellosis: A systematic review and network meta-analysis of randomized controlled trials[J]. PLoS Neglected Tropical Diseases, 2024.
[2] Alavi SM, Alavi L. Treatment of brucellosis: a systematic review of studies in recent twenty years[J]. Caspian Journal of Internal Medicine, 2013, 4(2): 636-641.
[3] Galvão EL, et al. Treatment of Childhood Brucellosis: A Systematic Review[J]. Pediatric Infectious Disease Journal, 2024, 43(9): 857-866.
[4] 中国创伤救治联盟新疆分中心.布鲁氏菌性骨关节炎诊断和治疗专家共识[J].中国组织工程研究,2026,30(9):2403-2412.
[5] 方千,等.神经型布鲁菌病的临床特点及诊治分析[J].中华实验和临床感染病杂志,2016,10(1).
[6] Hasanjani Roushan MR, et al. Comparison of the efficacy of two months of treatment with co-trimoxazole plus doxycycline vs. co-trimoxazole plus rifampin in brucellosis[J]. Swiss Medical Weekly, 2004, 134(37-38): 564-568.
[7] Huang S, et al. Updated therapeutic options for human brucellosis: A systematic review and network meta-analysis of randomized controlled trials[J]. PLoS Neglected Tropical Diseases, 2024.
Copyright © 2026 曾圣涛, 刘兵, 董良, 曾文涓
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License